Yoptimal, Health Professionals

Clinical studies / Scientific Proofs

Each 100-g serving of Yoptimal^TM contains more than 1 billion probiotics of each BB-12^® Bifidobacterium lactis and LA-5^® Lactobacillus acidophilus cultures that contribute to healthy tract flora. These bacteria have an international reputation, they are not Yoplait property. Studies conducted on these bacteria were not paid or subsidized by Yoplait. They were generated by the scientific community. Yoptimal^TM was developed after several years of research by INDEPENDENT researchers.

BB-12^® Bifidobacterium lactis is among the three most studied bacteria in the world. It has been used in dairy products for the last 20 years.

We drew up a list of articles with only type 1 level of evidence.

	Level of evidence		Where the evidence comes from
	1 Evidence with a high degree of reliability		Studies that use well tested methods to make comparisons in a fair way and where the results leave little room for uncertainty. Trial design: usually Level 1 studies are systematic reviews or large, high-quality randomised controlled studies
	2 Evidence with reliability but open to debate		Studies that use well tested methods to make comparisons in a fair way but where the results leave room for uncertainty (for example, due to the size of the study, losses to follow-up or the method used for selecting groups for comparison). Trial design: usually Level 2 studies are systematic reviews without consistent findings, small randomised controlled trials, randomised controlled trials in which larges numbers of participants are lost to follow-up, or cohort studies.
	3 Some evidence without a high degree of reliability		Studies where the results are doubtful because the study does not guarantee that fair comparisons can be made. Trial design: usually Level 3 studies are systematic reviews of case-control studies or individual case-control studies.
	4 Some evidence but based on studies without comparable groups		Studies where there is a high probability that results are due to chance (for example because there is no comparison group or because the groups compared were different at the outset of the study). Trial design: usually cohort or case-control studies where the groups were not really comparable, or case-series studies.

Clinical studies on BB-12^®Bifidobacterium lactis and LA-5^® Lactobacillus acidophilus on adults

Survival of probiotics in the intestinal gastro system

Ouwehand A.C, Kurvinen T., Rissanen P., Use of a probiotic Bifidobacterium in a dry food matrix, an in vivo study. 2004 Int J food microbiol. Aug 15;95 (1)

Sullivan Å, Barkholt L, Nord CE. Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic- associated ecological disturbances of Bacteroides fragilis in the intestine. 2003. Journal of Antimicrobial Chemotherapy, 52, 308-311.

Schiffrin, E.J., Rochat, F., Link-Amster, H., Aeschlimann, J.M., Donnet-Hughes, A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. 1995. Journal of Dairy Science, 78: 491-497

H pylori eradication

Sheu BS, J Wu, CY Lo, HW Wu, JH Chen, YS Lin & MD Lin. 2002. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yoghurt on triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 16, 1669-1675

Sheu BY, Cheng H-C, Kao A-W, Wang S-T, Yang Y-J, Yang H-B, Wu J-J. 2006. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of Quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr 83: 864-9.

References